

PANCAID'S FIRST STAKEHOLDER DIALOGUE EVENT

 BRUSSELS

 15 JANUARY 2025

 PANCREATIC
CANCER EUROPE

 uég

 PANCAID

Networking among research groups on Pancreatic Cancer: the PCE Research Map, an effort to enhance the cooperation among researchers


Núria Malats, MD, MPH, PhD

Spanish National Cancer Research Centre (CNIO)

nmalats@cnio.es

The Facts

Even now, **only 2%** of cancer projects funded by the European Commission during **2021-2024** focus on pancreatic cancer!!



How we work:



Awareness and Diagnosis

To raise awareness of the disease itself and the challenges faced by patients and their families and carers



Registries

To fill the gap in organised data collection in pancreatic cancer across Europe, and to lead to a better understanding of the disease



Treatment

To present treatment options, and to communicate best practices and essential requirements for quality of care



National Support

To support the work of PCE national member organisations, offering materials and actions



Research

To promote policies and research programmes to advance medical science on pancreatic cancer, and to help coordinate the pancreatic cancer research effort across Europe

Launched in 2015

European **multi-stakeholder** platform composed of more than **120** European experts from all over Europe, including **academics**, **physicians**, politicians, patient groups, and journalists with a common interest and willingness to improve care for patients with pancreatic cancer.

120 members
29 EU + 7 non-EU countries

Participation in European funded projects and Clinical Guidelines



2023 - present

5-year funded project

- Coordinated by UKE Hamburg-Eppendorf (Germany)
- 16 partners and 1 associated partner from 8 countries
- To develop a minimally invasive **blood test** using liquid biopsy to detect pancreatic cancer to facilitate **early detection** of the cancer and its precursors



Horizon Europe Mission on Cancer



2023 - present

5-year funded project

- Coordinated by IARC (France)
- 20 partners
- To understand the **causes** of renal, pancreatic, and colorectal cancer in Europe and to help explain the **geographical distribution** of these cancer types, including their high incidence in central and eastern Europe


2025 Multi-societal European Guideline on Pancreatic cancer



PCEMap: Pancreatic Cancer Research Groups in Europe

Provides a **real, dynamic, and detailed** picture of PC research in Europe by the **geographical setting, type of research, and availability of resources**

1. To increase the **visualization** of EU pancreatic cancer research teams at the international scenario
2. To promote pancreatic cancer scientific **collaborations**
3. To foster the **training** of young pancreatic cancer researchers
4. To serve the EU scientific policymakers as a “heatmap” to **identify deficiencies** in pancreatic cancer research in Europe
5. To provide the patients & general population **information** on pancreatic cancer research **projects**



656 Researchers
75 research teams
14 countries
(December 2024)

Research type:

Basic: 46
Translational: 53
Clinical: 33
Epidemiology: 13
Oncology: 40
Pathology: 15
Radiology: 10
Surgery: 16
Other: 2

Resources:

Biobank: 51
Cell lines: 46
Bioinformatics: 27
Clinical trials: 37
Databases: 35
Pop-based studies: 31
Registries: 24
Mouse models: 37

2nd Multistakeholder Brainstorming meeting

PANCREATIC CANCER RESEARCH IN EUROPE: “WHERE DO WE STAND AND WHICH SHOULD BE THE PRIORITIES?”

Madrid, 26 May 2023



- 36 participants
- 11 Countries (Belgium, France, Germany, Ireland, Israel, Italy, Lithuania, Netherlands, Poland, Rumania, Slovenia, Spain, Sweden, Switzerland, United Kingdom, USA)
- Researchers, Health Care Professionals, Patients, Advocates, Funding Agencies, Industry

AIMS

- 1) To identify the **main issues** that need to be addressed in **pancreatic cancer research in Europe**
- 2) To provide a **list of prioritized actions** to the European Commission, National Research Programs, Scientific Societies, and Cancer Funding Agencies

CONCLUSIONS

- 1) Invest in **primary prevention and early detection** of pancreatic cancer
- 2) Understand PDAC **mechanisms** and use **preclinical models** to accelerate clinical trial design
- 3) Enhancing excellence in **clinical research**
- 4) Increase pancreatic cancer **awareness** for **higher funding**

PANCAID'S FIRST STAKEHOLDER DIALOGUE EVENT

 BRUSSELS

 15 JANUARY 2025



Participation in European-funded projects & Clinical Guidelines

PCEMap of Pancreatic Cancer Research Groups in Europe

MBM: Multistakeholder Brainstorming Meetings



A Network of Registries on Pancreatic Cancer

S3A Awards for Early Career Investigators

Joan Guinovart (1947 – 2025, 77 years)



Spanish **biochemist** known for his research on glycogen and liver glycogen synthase, as well as for his work with FEBS, IUBMB, and the Spanish Society of Biochemistry and Molecular Biology.

From 2001 to 2002, he served as the **director general of the Barcelona Science Park**, where he established the Institute for Research in Biomedicine (IRB Barcelona) in 2005.

“This time I speak from the dual perspective of both the researcher and the patient.

It is essential to **attract more financial and human resources** to combat this disease.

The timelines for translational research must be expedited to shorten the duration between basic discoveries and their clinical applications. In this regard, **any bureaucratic obstacle becomes a limiting factor**. Every effort should be made to optimize the transfer processes, and here, national and European health authorities play a crucial role.”

PCEMap: Pancreatic Cancer Research Groups in Europe

Provides a real and detailed picture of PC research in Europe by the **geographical** setting, **type** of research, and availability of **resources**

1. Presenting a **comprehensive and dynamic overview** of pancreatic cancer research in Europe.
2. Increasing the **international visibility of European research teams**.
3. Promoting **scientific collaboration and innovation**.
4. Supporting the **training of young researchers** in the field.
5. Assisting policymakers with a "**heatmap**" to identify gaps and needs in pancreatic cancer research.
6. **Engaging** patients and the general public in research efforts.



656 Researchers
75 research teams
14 countries
(December 2024)

Research type:

Basic: 46
Translational: 53
Clinical: 33
Epidemiology: 13
Oncology: 40
Pathology: 15
Radiology: 10
Surgery: 16
Other: 2

Resources:






Biobank: 51
Cell lines: 46
Bioinformatics: 27
Clinical trials: 37
Databases: 35
Pop-based studies: 31
Registries: 24
Mouse models: 37

PancreOS compiles information from European registries on pancreatic cancer **diagnosis, treatment, and survival** to describe the patient management diversity among countries and to assess its impact


Objectives

- ✓ To implement a European network of pancreatic cancer registries **to provide a comprehensive view of pancreatic cancer patient management in Europe**
- ✓ To foster **the accuracy of pancreatic cancer data** gathering and reporting
- ✓ To stimulate and support **cooperation among registries**
- ✓ To promote a **better understanding of the disease** and the development of more effective management policies, diagnostic strategies, and personalized treatments

Registries already involved in PancreOS



- BACAP, France
- Slovenian Cancer Registry
- Swedish National Registry for PC
- PC Registry Hungary
- Cancer Registry of Baden-Württemberg, Germany
- Girona Cancer Registry, Spain
- Registro Tumores Castellón, Spain
- Murcia Cancer Registry, Spain
- TTD Pancreas Cancer Regis., Spain



S3A Awards for Early Career Investigators



2024
Jonathan Baldan
From Belgium to Spain



2022
Mjriam Capula
From Italy to The Netherlands



PCE launches yearly a call for **short-term scientific stay awards** to train one or more **Early Career Investigators (ECI)** on pancreatic cancer research with

NEXT CALL in February 2025

existing **networks of** pancreatic cancer research
Set up **new partnerships and collaborations** between high-level pancreatic cancer research institutions

[View this email in your browser.](#)



PCE Early Career Investigator (ECI) Short-term Scientific Stay Award (S3A) – 2023



PCE is launching a Short-Term Scientific Stay Award of (maximum) €5000, to train one or more Early Career Investigators (ECI) on Pancreatic Cancer research.
The eligible candidates are: ECIs with a completed PhD no more than 5 years ago; PhD students researching pancreatic cancer.

Research stay: 1-3 months, to be ended by 31 December 2023.

Deadline for submission: 17 April 2023.

Interested candidates should send the application form with the requested attachments, in English to contact@pancreaticcancereurope.eu by Monday, 17 April 2023.

[DOWNLOAD THE APPLICATION FORM](#)

1st Multistakeholder Brainstorming meeting

PANCREATIC CANCER RESEARCH IN EUROPE

Brussels, 12 April 2017



- 16 participants
- 9 Countries (Belgium, France, Germany, Portugal, Rumania, Spain, Sweden, United Kingdom)
- Researchers, Health Professionals, Advocates, Industry, MEP

AIMS

1. Identify, debate, select, and prioritize the **main aspects**
2. **Lobby** to increase **awareness** of PC research
3. **Report** the conclusions of the meeting to the European Commission, National Research Institutes and **disseminate** the report to the

CONCLUSIONS

- 1) Prioritize research into **diagnostic imaging** (MRI) features and biomarkers for **precancerous lesions** (cystic tumours, IPMN, and PanINs) according to
- 2) Prioritize research to define the **“optimal window of opportunity”** for **PC screening**
- 3) Prioritize research into the **identification of predictive markers** for response toward PC “personalized treatment”
- 4) Prioritize the establishment of **multistakeholder cooperative** teams including multidisciplinary research and health professional teams, private sector representative patients, health economics professionals, and policymakers

MBM 2025 on Early diagnosis of pancreatic cancer
(in preparation)

3rd Multistakeholder Brainstorming meeting

ACCESS TO TREATMENT FOR PANCREATIC CANCER PAT

Santiago de Compostela, 25 June 2024



- 33 participants
- 11 Countries (Belgium, Germany, France, Italy, Lithuania, Netherlands, Portugal, Spain, Sweden, Switzerland, United Kingdom)
- Researchers, Health Professionals, Patient Advocates, Regulatory Agencies, Industry

AIM: Sharing best practices and highlighting the challenges

TOPICS

- Patient priorities in treatment
- Best practices in identifying patients
- Best practices in SoC treatment: pre-operative, post-surgery, Treatment optimization, Targeted therapies
- Clinical trials: Best access for patients, Best development of clinical trials
- Holistic treatment: Expert oncology, Role of nutrition and Role of cachexia, End-of-life care
- Call to action: Implementation & dissemination, Guidelines, Engaging Societies for training & dissemination, Patient representative groups giving voice to the problem, Patient representative groups getting into action, Priority at the EU agenda, Point of view of pharma companies

MBM 2025 on Early diagnosis of pancreatic cancer
(in preparation)

MBM: Multistakeholder Brainstorming Meetings

ACCESS TO TREATMENT FOR PANCREATIC CANCER PATIENTS

Santiago de Compostela, 25 June 2024



PANCREATIC CANCER RESEARCH IN EUROPE: “WHERE DO WE STAND AND WHICH SHOULD BE THE PRIORITIES?”

Madrid, 26 May 2023



PANCREATIC CANCER RESEARCH IN EUROPE

Brussels, 12 April 2017

